Target	O
structures	O
of	O
the	O
CD8	O
(	O
+	O
)	O
-T-cell	O
response	O
to	O
human	O
cytomegalovirus	O
:	O
the	O
72-kilodalton	B-protein
major	I-protein
immediate-early	I-protein
protein	I-protein
revisited	O
.	O

Cell-mediated	O
immunity	O
plays	O
an	O
essential	O
role	O
in	O
the	O
control	O
of	O
infection	O
with	O
the	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
.	O

However	O
,	O
only	O
a	O
few	O
CD8	B-protein
(	I-protein
+	I-protein
)	I-protein
-T-cell	I-protein
epitopes	I-protein
are	O
known	O
,	O
with	O
the	O
majority	O
being	O
contained	O
in	O
the	O
pp65	B-protein
phosphoprotein	I-protein
,	O
which	O
is	O
believed	O
to	O
dominate	O
the	O
CD8	O
(	O
+	O
)	O
-T-cell	O
response	O
to	O
HCMV	O
.	O

Here	O
,	O
we	O
have	O
readdressed	O
the	O
issue	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
specific	O
for	O
the	O
72-kDa	B-protein
major	I-protein
immediate-early	I-protein
protein	I-protein
(	O
IE-1	B-protein
)	O
,	O
which	O
is	O
nonstructural	O
but	O
is	O
found	O
very	O
early	O
and	O
throughout	O
the	O
replicative	O
cycle	O
.	O

Using	O
a	O
novel	O
flow-cytometric	O
assay	O
,	O
we	O
were	O
able	O
to	O
identify	O
CD8	B-protein
(	I-protein
+	I-protein
)	I-protein
-T-cell	I-protein
epitopes	I-protein
(	O
by	O
IE-1	B-protein
peptide-specific	O
induction	O
of	O
cytokine	B-protein
synthesis	O
)	O
and	O
simultaneously	O
measure	O
the	O
frequency	O
of	O
cells	O
directed	O
against	O
them	O
.	O

For	O
this	O
purpose	O
,	O
81	O
pentadecamer	O
peptides	O
covering	O
the	O
complete	O
491-amino-acid	B-protein
sequence	I-protein
of	O
IE-1	B-protein
were	O
tested	O
on	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
anti-HCMV	O
immunoglobulin	O
G-seropositive	O
donors	O
.	O

At	O
least	O
10	O
new	O
epitopes	B-protein
were	O
identified	O
,	O
and	O
the	O
fine	O
specificity	O
and	O
presenting	O
HLA	B-protein
molecule	I-protein
of	O
the	O
first	O
of	O
them	O
was	O
determined	O
.	O

The	O
frequencies	O
of	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
directed	O
against	O
IE-1	B-protein
were	O
similar	O
to	O
those	O
directed	O
against	O
pp65	B-protein
in	O
donors	O
tested	O
with	O
known	O
pp65	B-protein
-derived	O
peptides	O
.	O

Importantly	O
,	O
additional	O
testing	O
of	O
a	O
corresponding	O
set	O
of	O
peptides	O
covering	O
the	O
complete	O
sequence	O
of	O
pp65	B-protein
on	O
10	O
of	O
these	O
donors	O
identified	O
individuals	O
whose	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
recognized	O
IE-1	B-protein
but	O
not	O
pp65	B-protein
and	O
vice	O
versa	O
,	O
clearly	O
illustrating	O
that	O
either	O
protein	O
may	O
be	O
a	O
major	O
target	O
.	O

In	O
summary	O
,	O
our	O
results	O
suggest	O
that	O
IE-1	B-protein
is	O
far	O
more	O
important	O
as	O
a	O
CD8	O
(	O
+	O
)	O
-T-cell	O
target	O
than	O
current	O
opinion	O
suggests	O
.	O

JournNaAL	NULL
or	NULL
VirRoLoGYy	NULL
,	NULL
Oct.	NULL
1999	NULL
,	NULL
p.	NULL
8179-8184	NULL
0022-538	NULL
X/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

73	NULL
,	NULL
No	NULL
.	NULL

10	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Target	NULL
Structures	NULL
of	NULL
the	NULL
CD8	NULL
*-T-Cell	NULL
Response	NULL
to	NULL
Human	NULL
Cytomegalovirus	NULL
:	NULL
the	NULL
72-Kilodalton	NULL
Major	NULL
Immediate-Early	NULL
Protein	NULL
Revisited	NULL
FLORIAN	NULL
KERN	NULL
,	NULL
'**	NULL
INGOLF	NULL
PASCAL	NULL
SUREL	NULL
,	NULL
'	NULL
NICOLE	NULL
FAI__JLHABER,1	NULL
’	NULL
2	NULL
CLAUDIA	NULL
FROMMEL	NULL
,	NULL
*	NULL
JENS	NULL
SCHNEIDER-MERGENER	NULL
,	NULL
'	NULL
CONSTANZE	NULL
SCHONEMANN	NULL
,	NULL
``	NULL
PETRA	NULL
REINKE	NULL
,	NULL
*	NULL
AND	NULL
HANS-DIETER	NULL
VOLK	NULL
!	NULL

Institut	NULL
fiir	NULL
Medizinische	NULL
Immunologie	NULL
,	NULL
Medizinische	NULL
Fakultiit	NULL
der	NULL
Humboldt-Universitiit	NULL
zu	NULL
Berlin	NULL
(	NULL
Charité	NULL
)	NULL
,	NULL
10098	NULL
Berlin	NULL
,	NULL
``	NULL
and	NULL
Medizinische	NULL
Klinik	NULL
mit	NULL
Schwerpunkt	NULL
Hiimatologie	NULL
und	NULL
Onkologie	NULL
(	NULL
Institut	NULL
fiir	NULL
Transfusionsmedizin	NULL
und	NULL
Immunhiimatologie	NULL
)	NULL
,	NULL
``	NULL
and	NULL
Medizinische	NULL
Klinik	NULL
mit	NULL
Schwerpunkt	NULL
Nephrologie	NULL
und	NULL
Intensivmedizin	NULL
,	NULL
*	NULL
Fakultiit	NULL
der	NULL
Humboldt-Universitiit	NULL
zu	NULL
Berlin	NULL
(	NULL
Charité	NULL
)	NULL
,	NULL
13353	NULL
Berlin	NULL
,	NULL
Germany	NULL
Received	NULL
26	NULL
April	NULL
1999/Accepted	NULL
28	NULL
June	NULL
1999	NULL
Cell-mediated	NULL
immunity	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
infection	NULL
with	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
(	NULL
HCMV	NULL
)	NULL
.	NULL

However	NULL
,	NULL
only	NULL
a	NULL
few	NULL
CD8	NULL
*-T-cell	NULL
epitopes	NULL
are	NULL
known	NULL
,	NULL
with	NULL
the	NULL
majority	NULL
being	NULL
contained	NULL
in	NULL
the	NULL
pp65	NULL
phosphoprotein	NULL
,	NULL
which	NULL
is	NULL
believed	NULL
to	NULL
dominate	NULL
the	NULL
CD8	NULL
*-T-cell	NULL
response	NULL
to	NULL
HCMV	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
readdressed	NULL
the	NULL
issue	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
specific	NULL
for	NULL
the	NULL
72-kDa	NULL
major	NULL
immediate-early	NULL
protein	NULL
(	NULL
IE-1	NULL
)	NULL
,	NULL
which	NULL
is	NULL
nonstructural	NULL
but	NULL
is	NULL
found	NULL
very	NULL
early	NULL
and	NULL
throughout	NULL
the	NULL
replicative	NULL
cycle	NULL
.	NULL

Using	NULL
a	NULL
novel	NULL
flow-cytometric	NULL
assay	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
identify	NULL
CD8	NULL
*-T-cell	NULL
epitopes	NULL
(	NULL
by	NULL
IE-1	NULL
peptide-specific	NULL
induction	NULL
of	NULL
cytokine	NULL
synthesis	NULL
)	NULL
and	NULL
simultaneously	NULL
measure	NULL
the	NULL
frequency	NULL
of	NULL
cells	NULL
directed	NULL
against	NULL
them	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
81	NULL
pentadecamer	NULL
peptides	NULL
covering	NULL
the	NULL
complete	NULL
491-amino-acid	NULL
sequence	NULL
of	NULL
IE-1	NULL
were	NULL
tested	NULL
on	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
of	NULL
anti-HCMV	NULL
immunoglobulin	NULL
G-seropositive	NULL
donors	NULL
.	NULL

At	NULL
least	NULL
10	NULL
new	NULL
epitopes	NULL
were	NULL
identified	NULL
,	NULL
and	NULL
the	NULL
fine	NULL
specificity	NULL
and	NULL
presenting	NULL
HLA	NULL
molecule	NULL
of	NULL
the	NULL
first	NULL
of	NULL
them	NULL
was	NULL
determined	NULL
.	NULL

The	NULL
frequencies	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
directed	NULL
against	NULL
IE-1	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
directed	NULL
against	NULL
pp65	NULL
in	NULL
donors	NULL
tested	NULL
with	NULL
known	NULL
pp65-derived	NULL
peptides	NULL
.	NULL

Impor-tantly	NULL
,	NULL
additional	NULL
testing	NULL
of	NULL
a	NULL
corresponding	NULL
set	NULL
of	NULL
peptides	NULL
covering	NULL
the	NULL
complete	NULL
sequence	NULL
of	NULL
pp65	NULL
on	NULL
10	NULL
of	NULL
these	NULL
donors	NULL
identified	NULL
individuals	NULL
whose	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
recognized	NULL
IE-1	NULL
but	NULL
not	NULL
pp65	NULL
and	NULL
vice	NULL
versa	NULL
,	NULL
clearly	NULL
illustrating	NULL
that	NULL
either	NULL
protein	NULL
may	NULL
be	NULL
a	NULL
major	NULL
target	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
IE-1	NULL
is	NULL
far	NULL
more	NULL
important	NULL
as	NULL
a	NULL
CD8	NULL
*-T-cell	NULL
target	NULL
than	NULL
current	NULL
opinion	NULL
suggests	NULL
.	NULL

Primary	NULL
infection	NULL
with	NULL
or	NULL
reactivation	NULL
of	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
(	NULL
HCMV	NULL
)	NULL
is	NULL
a	NULL
major	NULL
complication	NULL
after	NULL
bone	NULL
marrow	NULL
transplantation	NULL
and	NULL
solid-organ	NULL
transplantation	NULL
,	NULL
and	NULL
in	NULL
persons	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
11	NULL
,	NULL
19-21	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Cell-mediated	NULL
immunity	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
persistent	NULL
infection	NULL
,	NULL
induction	NULL
of	NULL
latency	NULL
,	NULL
and	NULL
recovery	NULL
from	NULL
acute	NULL
disease	NULL
(	NULL
11	NULL
,	NULL
14	NULL
,	NULL
15	NULL
,	NULL
19-21	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Adoptive	NULL
transfer	NULL
of	NULL
HCMV-specific	NULL
CD8	NULL
*-T-cell	NULL
clones	NULL
in	NULL
bone	NULL
marrow	NULL
transplant	NULL
recipients	NULL
has	NULL
successfully	NULL
prevented	NULL
viremia	NULL
and	NULL
disease	NULL
(	NULL
11	NULL
,	NULL
20	NULL
,	NULL
21	NULL
,	NULL
24	NULL
)	NULL
,	NULL
illustrating	NULL
the	NULL
importance	NULL
of	NULL
a	NULL
sufficient	NULL
CD8	NULL
*	NULL
-T	NULL
-cell	NULL
response	NULL
in	NULL
particular	NULL
.	NULL

Boosting	NULL
the	NULL
CD8	NULL
*-T-cell	NULL
response	NULL
with	NULL
HCMV-derived	NULL
peptides	NULL
could	NULL
potentially	NULL
be	NULL
a	NULL
useful	NULL
alternative	NULL
to	NULL
adoptive	NULL
T-cell	NULL
transfer	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
a	NULL
previously	NULL
defined	NULL
HLA-2.1-pre-sented	NULL
cytotoxic	NULL
T-lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
epitope	NULL
from	NULL
the	NULL
HCMV	NULL
pp65	NULL
protein	NULL
is	NULL
being	NULL
evaluated	NULL
as	NULL
a	NULL
candidate	NULL
for	NULL
vaccination	NULL
therapy	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Unfortunately	NULL
,	NULL
to	NULL
date	NULL
,	NULL
our	NULL
knowledge	NULL
of	NULL
HCMV	NULL
CD8	NULL
*-T-cell	NULL
epitopes	NULL
is	NULL
limited	NULL
to	NULL
only	NULL
a	NULL
few	NULL
,	NULL
most	NULL
of	NULL
which	NULL
originate	NULL
from	NULL
the	NULL
pp65	NULL
lower	NULL
matrix	NULL
phosphoprotein	NULL
(	NULL
UL83	NULL
)	NULL
(	NULL
25	NULL
)	NULL
and	NULL
some	NULL
of	NULL
which	NULL
originate	NULL
from	NULL
the	NULL
72-kDa	NULL
major	NULL
immediate-early	NULL
protein	NULL
(	NULL
IE-1	NULL
)	NULL
(	NULL
1	NULL
,	NULL
9	NULL
)	NULL
.	NULL

The	NULL
presenting	NULL
HLA	NULL
molecules	NULL
,	NULL
as	NULL
far	NULL
as	NULL
they	NULL
are	NULL
known	NULL
,	NULL
are	NULL
HLA-A2	NULL
,	NULL
HLA-B7	NULL
,	NULL
HLA-B8	NULL
,	NULL
HLA-B18	NULL
,	NULL
and	NULL
HLA-B35	NULL
(	NULL
1	NULL
,	NULL
9	NULL
,	NULL
25	NULL
)	NULL
,	NULL
so	NULL
that	NULL
only	NULL
approximately	NULL
50	NULL
to	NULL
60	NULL
%	NULL
of	NULL
a	NULL
Caucasian	NULL
population	NULL
could	NULL
theoretically	NULL
benefit	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Institut	NULL
fiir	NULL
Medizinische	NULL
Immunologie	NULL
der	NULL
Charité	NULL
,	NULL
Campus	NULL
Mitte	NULL
,	NULL
COZ	NULL
,	NULL
10098	NULL
Berlin	NULL
,	NULL
Germany	NULL
.	NULL

Phone	NULL
:	NULL
030-28022858	NULL
.	NULL

Fax	NULL
:	NULL
030-28025461	NULL
.	NULL

E-mail	NULL
:	NULL
florian.kern	NULL
@	NULL
charite.de	NULL
.	NULL

8179	NULL
from	NULL
vaccinations	NULL
or	NULL
immune	NULL
therapy	NULL
based	NULL
on	NULL
these	NULL
known	NULL
epitopes	NULL
.	NULL

Despite	NULL
the	NULL
existence	NULL
of	NULL
several	NULL
CTL	NULL
epitopes	NULL
in	NULL
IE-1	NULL
(	NULL
1	NULL
,	NULL
9	NULL
)	NULL
and	NULL
the	NULL
observation	NULL
of	NULL
IE-1-directed	NULL
CTL	NULL
activity	NULL
in	NULL
early	NULL
studies	NULL
on	NULL
the	NULL
anti-HCMV	NULL
T-cell	NULL
response	NULL
(	NULL
2	NULL
)	NULL
,	NULL
the	NULL
pp65	NULL
phosphoprotein	NULL
is	NULL
presently	NULL
believed	NULL
to	NULL
largely	NULL
dominate	NULL
the	NULL
anti-HCMV	NULL
CTL	NULL
response	NULL
(	NULL
13	NULL
,	NULL
25	NULL
)	NULL
.	NULL

This	NULL
is	NULL
partly	NULL
because	NULL
structural	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
pp65	NULL
,	NULL
which	NULL
is	NULL
presented	NULL
by	NULL
infected	NULL
cells	NULL
prior	NULL
to	NULL
virus	NULL
protein	NULL
synthesis	NULL
,	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
more	NULL
effective	NULL
targets	NULL
per	NULL
se	NULL
than	NULL
are	NULL
nonstructural	NULL
proteins	NULL
(	NULL
such	NULL
as	NULL
IE-1	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

That	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I-presented	NULL
peptides	NULL
are	NULL
typically	NULL
9	NULL
amino	NULL
acids	NULL
long	NULL
(	NULL
16-18	NULL
)	NULL
was	NULL
first	NULL
revealed	NULL
in	NULL
1991	NULL
(	NULL
8	NULL
)	NULL
and	NULL
later	NULL
reflected	NULL
in	NULL
the	NULL
use	NULL
of	NULL
at	NULL
least	NULL
nine	NULL
overlaps	NULL
in	NULL
the	NULL
design	NULL
of	NULL
peptides	NULL
used	NULL
for	NULL
epitope	NULL
mapping	NULL
.	NULL

The	NULL
only	NULL
major	NULL
study	NULL
attempting	NULL
to	NULL
map	NULL
CTL	NULL
epitopes	NULL
in	NULL
IE-1	NULL
was	NULL
in	NULL
fact	NULL
published	NULL
in	NULL
1991	NULL
and	NULL
used	NULL
only	NULL
six	NULL
overlaps	NULL
between	NULL
adjacent	NULL
peptides	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Because	NULL
pp65	NULL
had	NULL
only	NULL
recently	NULL
been	NULL
studied	NULL
with	NULL
regard	NULL
to	NULL
CTL	NULL
epitopes	NULL
by	NULL
using	NULL
a	NULL
modern	NULL
peptide	NULL
design	NULL
(	NULL
25	NULL
)	NULL
,	NULL
we	NULL
chose	NULL
IE-1	NULL
as	NULL
the	NULL
first	NULL
HCMV	NULL
protein	NULL
to	NULL
readdress	NULL
the	NULL
issue	NULL
of	NULL
CD8	NULL
*	NULL
-T	NULL
-cell	NULL
epitopes	NULL
by	NULL
using	NULL
a	NULL
novel	NULL
and	NULL
very	NULL
efficient	NULL
flow	NULL
cytometry-based	NULL
method	NULL
(	NULL
12	NULL
)	NULL
.	NULL

This	NULL
new	NULL
method	NULL
examines	NULL
rapid	NULL
peptide-specific	NULL
induction	NULL
of	NULL
effector	NULL
cytokine	NULL
synthesis	NULL
at	NULL
the	NULL
single-cell	NULL
level	NULL
(	NULL
12	NULL
)	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
81	NULL
15-amino-acid	NULL
peptides	NULL
(	NULL
nine	NULL
overlaps	NULL
between	NULL
adjacent	NULL
peptides	NULL
)	NULL
derived	NULL
from	NULL
the	NULL
491-amino-acid	NULL
protein	NULL
sequence	NULL
of	NULL
IE-1	NULL
(	NULL
SwissProt	NULL
accession	NULL
no	NULL
.	NULL

P13202	NULL
)	NULL
were	NULL
tested	NULL
on	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
from	NULL
20	NULL
HCMV-seropositive	NULL
healthy	NULL
blood	NULL
donors	NULL
.	NULL

At	NULL
least	NULL
10	NULL
15-amino-acid	NULL
peptides	NULL
that	NULL
induced	NULL
gamma	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
synthesis	NULL
in	NULL
subsets	NULL
of	NULL
donors	NULL
were	NULL
identified	NULL
.	NULL

For	NULL
the	NULL
first	NULL
one	NULL
of	NULL
these	NULL
,	NULL
we	NULL
have	NULL
now	NULL
determined	NULL
the	NULL
minimal	NULL
8180	NULL
KERN	NULL
ET	NULL
AL	NULL
.	NULL

epitope	NULL
and	NULL
the	NULL
presenting	NULL
HLA	NULL
molecule	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
measured	NULL
CD8	NULL
*-T	NULL
-cell	NULL
frequencies	NULL
were	NULL
of	NULL
the	NULL
same	NULL
order	NULL
of	NULL
magnitude	NULL
as	NULL
those	NULL
elicited	NULL
by	NULL
known	NULL
pp65-derived	NULL
peptides	NULL
in	NULL
HLA-A2-	NULL
and	NULL
HLA-B7-positive	NULL
donors	NULL
(	NULL
12	NULL
)	NULL
.	NULL

More	NULL
importantly	NULL
even	NULL
,	NULL
additional	NULL
testing	NULL
with	NULL
a	NULL
corresponding	NULL
set	NULL
of	NULL
15-amino-acid	NULL
peptides	NULL
covering	NULL
the	NULL
complete	NULL
sequence	NULL
of	NULL
pp65	NULL
in	NULL
some	NULL
of	NULL
the	NULL
donors	NULL
identified	NULL
several	NULL
subjects	NULL
with	NULL
a	NULL
strong	NULL
CD8	NULL
*-T-cell	NULL
response	NULL
against	NULL
IE-1	NULL
but	NULL
not	NULL
pp65	NULL
.	NULL

Conversely	NULL
,	NULL
we	NULL
identified	NULL
several	NULL
donors	NULL
who	NULL
had	NULL
no	NULL
CD8	NULL
*	NULL
-T	NULL
-cell	NULL
response	NULL
to	NULL
IE-1	NULL
but	NULL
did	NULL
show	NULL
a	NULL
response	NULL
to	NULL
pp6S5-derived	NULL
peptides	NULL
.	NULL

These	NULL
results	NULL
may	NULL
have	NULL
important	NULL
implications	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
putative	NULL
role	NULL
of	NULL
IE-1	NULL
as	NULL
a	NULL
factor	NULL
in	NULL
HCMV-associated	NULL
immune	NULL
system	NULL
pathology	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
in	NULL
some	NULL
individuals	NULL
IE-1	NULL
may	NULL
be	NULL
of	NULL
the	NULL
same	NULL
importance	NULL
as	NULL
pp65	NULL
,	NULL
and	NULL
in	NULL
a	NULL
subset	NULL
who	NULL
do	NULL
not	NULL
have	NULL
pp65-specific	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
IE-1	NULL
may	NULL
even	NULL
dominate	NULL
the	NULL
CD8	NULL
*	NULL
immune	NULL
response	NULL
(	NULL
possibly	NULL
together	NULL
with	NULL
yet	NULL
unidentified	NULL
epitopes	NULL
from	NULL
other	NULL
proteins	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Citrated	NULL
blood	NULL
was	NULL
obtained	NULL
from	NULL
HLA-typed	NULL
HCMV-seropositive	NULL
(	NULL
immuno-globulin	NULL
G	NULL
IgG	NULL
)	NULL
blood	NULL
donors	NULL
.	NULL

Following	NULL
standard	NULL
Ficoll-Paque	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
density	NULL
centrifugation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
sterile	NULL
phos-phate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
;	NULL
Gibco-BRL	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Bio-chrom	NULL
,	NULL
Berlin	NULL
,	NULL
Germany	NULL
)	NULL
containing	NULL
0.1	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
Bio-chrom	NULL
)	NULL
and	NULL
50	NULL
mM	NULL
glutamine	NULL
(	NULL
Biochrom	NULL
)	NULL
,	NULL
and	NULL
adjusted	NULL
to	NULL
10	NULL
``	NULL
cells/ml	NULL
.	NULL

Then	NULL
200	NULL
pl	NULL
each	NULL
of	NULL
cell	NULL
suspensions	NULL
and	NULL
peptide	NULL
solutions	NULL
(	NULL
10	NULL
pg/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
0.1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
)	NULL
were	NULL
placed	NULL
in	NULL
Cellstar	NULL
polystyrene	NULL
tubes	NULL
(	NULL
Greiner	NULL
,	NULL
Frickenhausen	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
placed	NULL
in	NULL
an	NULL
incubator	NULL
(	NULL
5°	NULL
slant	NULL
)	NULL
at	NULL
37°C	NULL
under	NULL
a	NULL
humidified	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
atmosphere	NULL
.	NULL

After	NULL
1	NULL
h	NULL
,	NULL
1,600	NULL
pl	NULL
of	NULL
RPMI	NULL
1640	NULL
containing	NULL
12.5	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Biochrom	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
glutamine	NULL
,	NULL
and	NULL
12.5	NULL
pg	NULL
of	NULL
brefeldin	NULL
A	NULL
(	NULL
Sigma	NULL
,	NULL
Munich	NULL
,	NULL
Germany	NULL
)	NULL
per	NULL
ml	NULL
was	NULL
added	NULL
.	NULL

After	NULL
an	NULL
additional	NULL
5	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
cold	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
PBS-1	NULL
mM	NULL
EDTA	NULL
(	NULL
Merck	NULL
,	NULL
Darmstadt	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
,	NULL
and	NULL
washed	NULL
again	NULL
with	NULL
cold	NULL
PBS	NULL
.	NULL

After	NULL
surface	NULL
staining	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
in	NULL
the	NULL
dark	NULL
)	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
fixed	NULL
for	NULL
5	NULL
min	NULL
at	NULL
37°C	NULL
in	NULL
PBS	NULL
containing	NULL
4	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
paraformaldehyde	NULL
(	NULL
Merck	NULL
)	NULL
and	NULL
washed	NULL
in	NULL
PBS	NULL
prior	NULL
to	NULL
permeabilization	NULL
(	NULL
permeabilizing	NULL
solution	NULL
;	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
as	NULL
specified	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Following	NULL
intracellular	NULL
staining	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
FACScalibur	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
by	NULL
using	NULL
the	NULL
CellQuestTM	NULL
software	NULL
package	NULL
.	NULL

Unstimulated	NULL
samples	NULL
were	NULL
analyzed	NULL
to	NULL
verify	NULL
the	NULL
effect	NULL
of	NULL
stimulation	NULL
.	NULL

Data	NULL
files	NULL
were	NULL
analyzed	NULL
with	NULL
CellQuest	NULL
or	NULL
Paint-a-Gate	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

On	NULL
day	NULL
1	NULL
,	NULL
candidate	NULL
peptides	NULL
were	NULL
selected	NULL
according	NULL
to	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
pooled	NULL
peptides	NULL
.	NULL

These	NULL
candidate	NULL
peptides	NULL
were	NULL
tested	NULL
individually	NULL
on	NULL
day	NULL
2	NULL
.	NULL

For	NULL
that	NULL
purpose	NULL
,	NULL
PBMC	NULL
from	NULL
day	NULL
1	NULL
were	NULL
kept	NULL
in	NULL
a	NULL
standard	NULL
incubator	NULL
.	NULL

Stimulation	NULL
was	NULL
performed	NULL
with	NULL
individual	NULL
peptides	NULL
by	NULL
the	NULL
same	NULL
method	NULL
as	NULL
on	NULL
day	NULL
1	NULL
,	NULL
ic	NULL
.	NULL

,	NULL
with	NULL
the	NULL
same	NULL
concentration	NULL
of	NULL
individual	NULL
peptides	NULL
as	NULL
within	NULL
the	NULL
peptide	NULL
pool	NULL
.	NULL

Parallel	NULL
stimulation	NULL
with	NULL
(	NULL
noncandidate	NULL
)	NULL
control	NULL
peptides	NULL
and	NULL
unstimulated	NULL
samples	NULL
was	NULL
always	NULL
performed	NULL
to	NULL
rule	NULL
out	NULL
unspecific	NULL
stimulation	NULL
.	NULL

Antibodies	NULL
and	NULL
peptides	NULL
.	NULL

Fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
anti-IFN-y	NULL
,	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
anti-CD69	NULL
,	NULL
Peridinin-chlorophyl-protein	NULL
(	NULL
PerCP	NULL
)	NULL
-conjugated	NULL
anti-CD8	NULL
,	NULL
allophyocyanin	NULL
(	NULL
APC	NULL
)	NULL
-conjugated	NULL
anti-CD3	NULL
,	NULL
and	NULL
the	NULL
corresponding	NULL
isotype-	NULL
and	NULL
fluorescent	NULL
conjugate-matched	NULL
control	NULL
reagents	NULL
were	NULL
purchased	NULL
from	NULL
Becton	NULL
Dickinson	NULL
.	NULL

Peptides	NULL
(	NULL
synthesized	NULL
by	NULL
the	NULL
standard	NULL
Fmoc	NULL
method	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
NMI	NULL
(	NULL
Reutlingen	NULL
,	NULL
Germany	NULL
)	NULL
or	NULL
produced	NULL
at	NULL
our	NULL
own	NULL
facility	NULL
.	NULL

Peptides	NULL
were	NULL
stored	NULL
freeze-dried	NULL
or	NULL
in	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
)	NULL
at	NULL
4	NULL
mg/ml	NULL
.	NULL

Peptide	NULL
pools	NULL
were	NULL
generated	NULL
from	NULL
peptides	NULL
dissolved	NULL
in	NULL
DMSO	NULL
.	NULL

DMSO	NULL
concentrations	NULL
in	NULL
all	NULL
assay	NULL
mixtures	NULL
were	NULL
kept	NULL
below	NULL
0.1	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
.	NULL

RESULTS	NULL
AND	NULL
DISCUSSION	NULL
Measurement	NULL
of	NULL
peptide-specific	NULL
induction	NULL
of	NULL
IFN-y	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
is	NULL
a	NULL
rapid	NULL
and	NULL
efficient	NULL
way	NULL
to	NULL
identify	NULL
CD8	NULL
-T-cell	NULL
epitopes	NULL
(	NULL
12	NULL
)	NULL
.	NULL

By	NULL
testing	NULL
81	NULL
overlapping	NULL
peptides	NULL
,	NULL
the	NULL
complete	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
IE-1	NULL
protein	NULL
was	NULL
covered	NULL
.	NULL

Peptide	NULL
pools	NULL
were	NULL
set	NULL
up	NULL
in	NULL
such	NULL
a	NULL
way	NULL
that	NULL
every	NULL
peptide	NULL
was	NULL
contained	NULL
in	NULL
exactly	NULL
two	NULL
pools	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
was	NULL
possible	NULL
to	NULL
identify	NULL
candidate	NULL
peptides	NULL
by	NULL
testing	NULL
not	NULL
more	NULL
than	NULL
18	NULL
peptide	NULL
pools	NULL
on	NULL
day	NULL
1	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
following	NULL
day	NULL
,	NULL
selected	NULL
candidate	NULL
peptides	NULL
were	NULL
tested	NULL
individually	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
PBMC	NULL
from	NULL
the	NULL
same	NULL
donors	NULL
had	NULL
been	NULL
kept	NULL
in	NULL
complete	NULL
medium	NULL
in	NULL
a	NULL
standard	NULL
incubator	NULL
overnight	NULL
.	NULL

Interestingly	NULL
,	NULL
stimulation	NULL
with	NULL
J.	NULL
Virou	NULL
.	NULL

1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
}	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
11	NULL
}	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
12\19	NULL
20	NULL
21	NULL
22	NULL
23	NULL
24	NULL
25	NULL
26	NULL
27	NULL
13	NULL
]	NULL
28	NULL
29	NULL
30	NULL
31	NULL
32	NULL
33	NULL
34	NULL
35	NULL
36	NULL
14	NULL
)	NULL
37	NULL
38	NULL
39	NULL
40	NULL
41	NULL
42	NULL
43	NULL
44	NULL
45	NULL
1546	NULL
47	NULL
48	NULL
49	NULL
50	NULL
51	NULL
52	NULL
53	NULL
54	NULL
16|55	NULL
56	NULL
57	NULL
58	NULL
59	NULL
60:61	NULL
62	NULL
63	NULL
17/64	NULL
65	NULL
66	NULL
67	NULL
68	NULL
69	NULL
70	NULL
71	NULL
72	NULL
18|73	NULL
74	NULL
75	NULL
76	NULL
77	NULL
78	NULL
79	NULL
80	NULL
81	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Design	NULL
of	NULL
peptide	NULL
pools	NULL
.	NULL

The	NULL
numbers	NULL
of	NULL
the	NULL
pools	NULL
(	NULL
left	NULL
column	NULL
and	NULL
top	NULL
row	NULL
)	NULL
are	NULL
shown	NULL
in	NULL
bold	NULL
.	NULL

Individual	NULL
peptides	NULL
(	NULL
#	NULL
=	NULL
81	NULL
)	NULL
in	NULL
these	NULL
18	NULL
pools	NULL
correspond	NULL
to	NULL
the	NULL
numbers	NULL
in	NULL
the	NULL
respective	NULL
columns	NULL
and	NULL
rows	NULL
,	NULL
with	NULL
peptide	NULL
1	NULL
=	NULL
IE-1	NULL
,	NULL
;	NULL
,	NULL
,	NULL
peptide	NULL
2	NULL
=	NULL
IE-1	NULL
;	NULL
;	NULL
;	NULL
,	NULL
etc	NULL
.	NULL

,	NULL
according	NULL
to	NULL
the	NULL
complete	NULL
sequence	NULL
of	NULL
the	NULL
72-kDa	NULL
major	NULL
IE	NULL
protein	NULL
.	NULL

previously	NULL
identified	NULL
pp6S5-derived	NULL
peptides	NULL
(	NULL
12	NULL
)	NULL
on	NULL
days	NULL
1	NULL
and	NULL
2	NULL
revealed	NULL
that	NULL
this	NULL
preincubation	NULL
slightly	NULL
increased	NULL
the	NULL
frequency	NULL
of	NULL
responding	NULL
CD8	NULL
T	NULL
cells	NULL
without	NULL
increasing	NULL
nonspecific	NULL
stimulation	NULL
as	NULL
tested	NULL
with	NULL
an	NULL
irrelevant	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
top	NULL
right	NULL
)	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
this	NULL
effect	NULL
was	NULL
due	NULL
to	NULL
preactivation	NULL
of	NULL
antigen-presenting	NULL
cells	NULL
and/or	NULL
a	NULL
reduction	NULL
of	NULL
inhibitory	NULL
monocytic	NULL
activity	NULL
.	NULL

The	NULL
shading	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
illustrates	NULL
how	NULL
candidate	NULL
peptides	NULL
were	NULL
chosen	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
positive	NULL
pools	NULL
,	NULL
7	NULL
and	NULL
15	NULL
,	NULL
clearly	NULL
identifies	NULL
the	NULL
candidate	NULL
peptide	NULL
52	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
IE-13,7-37	NULL
,	NULL
,	NULL
the	NULL
only	NULL
one	NULL
contained	NULL
in	NULL
both	NULL
pools	NULL
)	NULL
.	NULL

Figure	NULL
2	NULL
corresponds	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
shows	NULL
the	NULL
CD8	NULL
*-T-cell	NULL
IFN-y	NULL
responses	NULL
obtained	NULL
with	NULL
six	NULL
different	NULL
pools	NULL
,	NULL
the	NULL
two	NULL
positive	NULL
pools	NULL
and	NULL
the	NULL
four	NULL
``	NULL
neighboring	NULL
``	NULL
negative	NULL
pools	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
14	NULL
,	NULL
and	NULL
16	NULL
.	NULL

Table	NULL
1	NULL
summarizes	NULL
the	NULL
results	NULL
from	NULL
15	NULL
experiments	NULL
with	NULL
samples	NULL
from	NULL
healthy	NULL
HCMV	NULL
IgG-seropositive	NULL
donors	NULL
,	NULL
which	NULL
led	NULL
to	NULL
the	NULL
identification	NULL
of	NULL
several	NULL
CD8	NULL
*	NULL
-T	NULL
-cell-inducing	NULL
IE-1-derived	NULL
peptides	NULL
.	NULL

Table	NULL
1	NULL
also	NULL
shows	NULL
the	NULL
results	NULL
obtained	NULL
by	NULL
testing	NULL
a	NULL
corresponding	NULL
set	NULL
of	NULL
15-amino-acid	NULL
peptides	NULL
covering	NULL
the	NULL
complete	NULL
sequence	NULL
of	NULL
the	NULL
pp65	NULL
protein	NULL
(	NULL
SwissProt	NULL
accession	NULL
no	NULL
.	NULL

PO6725	NULL
)	NULL
in	NULL
10	NULL
of	NULL
these	NULL
donors	NULL
.	NULL

Among	NULL
the	NULL
IE-1-derived	NULL
peptides	NULL
,	NULL
IE-1	NULL
;	NULL
;	NULL
,	NULL
;	NULL
;	NULL
;	NULL
,	NULL
(	NULL
EFCRVLC	NULL
CYVLEETS	NULL
)	NULL
,	NULL
IE-1	NULL
;	NULL
93	NULL
2p	NULL
;	NULL
(	NULL
ARAKKDELRRKMMYM	NULL
)	NULL
,	NULL
and	NULL
IE-11s99	NULL
713	NULL
(	NULL
ELRRKMMYMCYRNIE	NULL
)	NULL
were	NULL
the	NULL
most	NULL
frequently	NULL
identified	NULL
.	NULL

All	NULL
donors	NULL
reactive	NULL
to	NULL
IE-1	NULL
;	NULL
,	NULL
,	NULL
;	NULL
;	NULL
,	NULL
were	NULL
HLA-B7	NULL
,	NULL
HLA-Bw6	NULL
,	NULL
and	NULL
HLA-Cw7	NULL
positive	NULL
(	NULL
D1	NULL
,	NULL
D2	NULL
,	NULL
D3	NULL
,	NULL
and	NULL
D4	NULL
)	NULL
;	NULL
however	NULL
,	NULL
donors	NULL
who	NULL
were	NULL
HLA-Cw	NULL
?	NULL

7	NULL
or	NULL
HLA-Bw6	NULL
but	NULL
not	NULL
HLA-B7	NULL
positive	NULL
did	NULL
not	NULL
react	NULL
to	NULL
this	NULL
peptide	NULL
(	NULL
for	NULL
example	NULL
D5	NULL
,	NULL
D6	NULL
,	NULL
D9	NULL
,	NULL
D10	NULL
,	NULL
and	NULL
D11	NULL
)	NULL
,	NULL
identifying	NULL
HLA-B7	NULL
as	NULL
the	NULL
presenting	NULL
allomorph	NULL
.	NULL

To	NULL
define	NULL
the	NULL
epitope	NULL
contained	NULL
in	NULL
IE-1	NULL
;	NULL
,	NULL
,	NULL
_	NULL
,	NULL
,	NULL
,	NULL
more	NULL
pre-cisely	NULL
,	NULL
all	NULL
seven	NULL
consecutive	NULL
9-amino-acid	NULL
peptides	NULL
derived	NULL
from	NULL
its	NULL
sequence	NULL
were	NULL
synthesized	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
IE-l39	NULL
415	NULL
IE-1309-317	NULL
,	NULL
through	NULL
IE-1	NULL
;	NULL
;	NULL
;	NULL
;	NULL
;	NULL
,	NULL
)	NULL
and	NULL
tested	NULL
in	NULL
two	NULL
donors	NULL
.	NULL

Several	NULL
of	NULL
these	NULL
nonamer	NULL
peptides	NULL
were	NULL
able	NULL
to	NULL
stimulate	NULL
IFN-y	NULL
induction	NULL
.	NULL

In	NULL
both	NULL
donors	NULL
,	NULL
;	NULL
;	NULL
;	NULL
induced	NULL
the	NULL
highest	NULL
frequency	NULL
of	NULL
CD8¢*	NULL
T	NULL
cells	NULL
(	NULL
0.84	NULL
and	NULL
0.64	NULL
%	NULL
)	NULL
,	NULL
IE-l310	NULL
31s	NULL
gave	NULL
a	NULL
somewhat	NULL
smaller	NULL
response	NULL
(	NULL
0.50	NULL
and	NULL
0.42	NULL
%	NULL
)	NULL
,	NULL
and	NULL
two	NULL
additional	NULL
consecutive	NULL
peptides	NULL
,	NULL
IE-1399	NULL
317	NULL
and	NULL
31g	NULL
,	NULL
gave	NULL
increasingly	NULL
weak	NULL
responses	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

These	NULL
different	NULL
frequencies	NULL
of	NULL
responding	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
obtained	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
largely	NULL
overlapping	NULL
peptides	NULL
suggested	NULL
that	NULL
T	NULL
cells	NULL
of	NULL
overlapping	NULL
or	NULL
different	NULL
speci-	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
peptide	NULL
pools	NULL
-	NULL
day	NULL
one	NULL
CD8	NULL
*-T-CELL	NULL
RESPONSE	NULL
TO	NULL
THE	NULL
HCMV	NULL
IE-1	NULL
PROTEIN	NULL
8181	NULL
single	NULL
peptide	NULL
-	NULL
day	NULL
2	NULL
pool	NULL
6	NULL
10	NULL
ao	NULL
4g	NULL
¢	NULL
10	NULL
IE-1307-321	NULL
Sare	NULL
%	NULL
10°	NULL
10°	NULL
E	NULL
10	NULL
)	NULL
10°	NULL
1	NULL
10	NULL
'	NULL
I	NULL
10	NULL
10	NULL
104	NULL
IFEN-y-FITC	NULL
-	NULL
»	NULL
10	NULL
o	NULL
¢	NULL
1G	NULL
10	NULL
108	NULL
10	NULL
%	NULL
(	NULL
CD8-PerCP	NULL
~	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-108	NULL
1¢	NULL
ao	NULL
)	NULL
ao	NULL
aot	NULL
9	NULL
10	NULL
®	NULL
®	NULL
3	NULL
pool	NULL
16	NULL
&	NULL
IE-1307-321	NULL
§	NULL
ts	NULL
f	NULL
®	NULL
o	NULL
®	NULL
4	NULL
10	NULL
ioo	NULL
¢	NULL
0	NULL
10	NULL
10	NULL
00	NULL
¢	NULL
10	NULL
10	NULL
10	NULL
ao	NULL
¢	NULL
¢	NULL
10	NULL
-	NULL
10	NULL
ao	NULL
)	NULL
¢	NULL
1G	NULL
io	NULL
IEN-y-FITC	NULL
»	NULL
isotype-FITC	NULL
-	NULL
»	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
CD8	NULL
*-T-cell	NULL
inducing	NULL
peptide	NULL
from	NULL
peptide	NULL
pools	NULL
.	NULL

Stimulation	NULL
of	NULL
PBMC	NULL
from	NULL
an	NULL
HCMV	NULL
IgG-seropositive	NULL
donor	NULL
with	NULL
overlapping	NULL
15-amino-acid	NULL
peptides	NULL
originating	NULL
from	NULL
the	NULL
IE-1	NULL
protein	NULL
.	NULL

The	NULL
figure	NULL
shows	NULL
results	NULL
obtained	NULL
with	NULL
six	NULL
different	NULL
peptide	NULL
pools	NULL
on	NULL
day	NULL
1	NULL
,	NULL
two	NULL
of	NULL
which	NULL
(	NULL
pool	NULL
7	NULL
and	NULL
pool	NULL
15	NULL
)	NULL
gave	NULL
positive	NULL
results	NULL
,	NULL
and	NULL
stimulation	NULL
with	NULL
the	NULL
candidate	NULL
peptide	NULL
IE-1	NULL
,	NULL
,	NULL
;	NULL
;	NULL
,	NULL
,	NULL
(	NULL
EFCRVLCCYVLEETS	NULL
)	NULL
,	NULL
the	NULL
only	NULL
peptide	NULL
contained	NULL
in	NULL
both	NULL
positive	NULL
pools	NULL
,	NULL
on	NULL
day	NULL
2	NULL
.	NULL

IFN-y-positive	NULL
events	NULL
are	NULL
highlighted	NULL
.	NULL

Results	NULL
for	NULL
50,000	NULL
CD3	NULL
T	NULL
cells	NULL
are	NULL
displayed	NULL
in	NULL
each	NULL
diagram	NULL
.	NULL

PBMC	NULL
were	NULL
stained	NULL
with	NULL
anti-IFN-y-FITC	NULL
,	NULL
anti-CD69-PE	NULL
,	NULL
anti-CD8-PerCP	NULL
,	NULL
and	NULL
anti-CD3-APC	NULL
.	NULL

Axes	NULL
show	NULL
log	NULL
fluorescence	NULL
intensity	NULL
.	NULL

ficities	NULL
were	NULL
addressed	NULL
or	NULL
that	NULL
,	NULL
owing	NULL
to	NULL
the	NULL
relatively	NULL
high	NULL
concentrations	NULL
of	NULL
peptides	NULL
we	NULL
used	NULL
(	NULL
on	NULL
the	NULL
order	NULL
of	NULL
10°	NULL
mol/	NULL
liter	NULL
)	NULL
,	NULL
the	NULL
incomplete	NULL
epitope	NULL
also	NULL
stimulated	NULL
T-cell	NULL
cytokine	NULL
induction	NULL
in	NULL
much	NULL
the	NULL
same	NULL
way	NULL
as	NULL
incomplete	NULL
epitopes	NULL
can	NULL
induce	NULL
target	NULL
cell	NULL
lysis	NULL
in	NULL
CTL	NULL
assays	NULL
if	NULL
their	NULL
concentrations	NULL
are	NULL
high	NULL
enough	NULL
(	NULL
7	NULL
)	NULL
.	NULL

This	NULL
will	NULL
have	NULL
to	NULL
be	NULL
examined	NULL
in	NULL
additional	NULL
experiments	NULL
.	NULL

Finally	NULL
,	NULL
to	NULL
show	NULL
that	NULL
previous	NULL
infection	NULL
with	NULL
CMV	NULL
was	NULL
necessary	NULL
for	NULL
cytokine	NULL
induction	NULL
by	NULL
IE-1	NULL
;	NULL
,	NULL
,	NULL
,	NULL
;	NULL
;	NULL
,	NULL
,	NULL
we	NULL
tested	NULL
this	NULL
peptide	NULL
on	NULL
PBMC	NULL
from	NULL
three	NULL
HCMV-seronegative	NULL
,	NULL
HLA-B7-positive	NULL
donors	NULL
under	NULL
identical	NULL
conditions	NULL
but	NULL
observed	NULL
no	NULL
response	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
bottom	NULL
)	NULL
.	NULL

Phorbol	NULL
myristate	NULL
acetate/iono-mycin	NULL
stimulation	NULL
performed	NULL
in	NULL
parallel	NULL
showed	NULL
that	NULL
the	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
all	NULL
individuals	NULL
were	NULL
able	NULL
to	NULL
produce	NULL
cytokines	NULL
upon	NULL
stimulation	NULL
.	NULL

We	NULL
assumed	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
reactivity	NULL
to	NULL
this	NULL
peptide	NULL
in	NULL
our	NULL
HLA-B7-positive	NULL
donors	NULL
was	NULL
indeed	NULL
dependent	NULL
on	NULL
immunization	NULL
with	NULL
HCMV	NULL
and	NULL
not	NULL
likely	NULL
to	NULL
result	NULL
from	NULL
cross-reactivity	NULL
with	NULL
peptides	NULL
of	NULL
different	NULL
origin	NULL
.	NULL

Unlike	NULL
IE-13	NULL
,	NULL
;	NULL
37	NULL
,	NULL
,	NULL
the	NULL
other	NULL
identified	NULL
epitopes	NULL
did	NULL
not	NULL
allow	NULL
for	NULL
easy	NULL
determination	NULL
of	NULL
their	NULL
presenting	NULL
HLA	NULL
molecule	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
peptides	NULL
IE-1	NULL
;	NULL
93	NULL
397	NULL
and	NULL
IE-1199	NULL
313	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
share	NULL
9	NULL
amino	NULL
acids	NULL
,	NULL
suggesting	NULL
that	NULL
in	NULL
donors	NULL
who	NULL
were	NULL
reactive	NULL
to	NULL
both	NULL
peptides	NULL
(	NULL
DS	NULL
and	NULL
D11	NULL
[	NULL
Table	NULL
1	NULL
]	NULL
)	NULL
this	NULL
overlap	NULL
may	NULL
define	NULL
the	NULL
epitope	NULL
.	NULL

Interestingly	NULL
,	NULL
computerized	NULL
binding	NULL
motif	NULL
analysis	NULL
carried	NULL
out	NULL
by	NULL
SYFPEITHI	NULL
(	NULL
16	NULL
)	NULL
,	NULL
a	NULL
computer	NULL
program	NULL
based	NULL
on	NULL
listings	NULL
of	NULL
MHC	NULL
ligands	NULL
and	NULL
binding	NULL
motifs	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
predicted	NULL
HLA-B8	NULL
as	NULL
the	NULL
most	NULL
likely	NULL
presenting	NULL
allomorph	NULL
for	NULL
this	NULL
candidate	NULL
epitope	NULL
.	NULL

An	NULL
even	NULL
higher	NULL
score	NULL
,	NULL
however	NULL
,	NULL
was	NULL
obtained	NULL
for	NULL
HLA-Al	NULL
and	NULL
the	NULL
decapeptide	NULL
,	NULL
IE-lj9g	NULL
207	NULL
(	NULL
DELRRKMMYM	NULL
[	NULL
contained	NULL
only	NULL
in	NULL
IE-1	NULL
;	NULL
5	NULL
;	NULL
;	NULL
,	NULL
;	NULL
]	NULL
)	NULL
.	NULL

Neverthe-	NULL
less	NULL
,	NULL
at	NULL
this	NULL
stage	NULL
the	NULL
data	NULL
is	NULL
inconclusive	NULL
,	NULL
because	NULL
although	NULL
HLA-A1	NULL
and	NULL
HLA-B8	NULL
are	NULL
found	NULL
in	NULL
all	NULL
donors	NULL
reactive	NULL
to	NULL
one	NULL
or	NULL
both	NULL
of	NULL
these	NULL
peptides	NULL
(	NULL
D4	NULL
,	NULL
DS	NULL
,	NULL
D10	NULL
,	NULL
and	NULL
D11	NULL
)	NULL
,	NULL
other	NULL
donors	NULL
with	NULL
just	NULL
HLA-A1	NULL
(	NULL
D8	NULL
and	NULL
D12	NULL
)	NULL
,	NULL
just	NULL
HLA-B8	NULL
(	NULL
D15	NULL
)	NULL
,	NULL
or	NULL
both	NULL
HLA-A1	NULL
and	NULL
HLA-B8	NULL
(	NULL
D6	NULL
)	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
either	NULL
.	NULL

Fine	NULL
mapping	NULL
of	NULL
the	NULL
epitope	NULL
(	NULL
s	NULL
)	NULL
with	NULL
smaller	NULL
peptides	NULL
,	NULL
however	NULL
,	NULL
is	NULL
likely	NULL
to	NULL
give	NULL
additional	NULL
clues	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
despite	NULL
the	NULL
identification	NULL
of	NULL
many	NULL
new	NULL
epitopes	NULL
and	NULL
high	NULL
frequencies	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
directed	NULL
against	NULL
them	NULL
in	NULL
some	NULL
donors	NULL
,	NULL
samples	NULL
from	NULL
other	NULL
individuals	NULL
tested	NULL
with	NULL
the	NULL
complete	NULL
set	NULL
of	NULL
IE-1	NULL
peptides	NULL
showed	NULL
no	NULL
response	NULL
to	NULL
any	NULL
of	NULL
them	NULL
.	NULL

Testing	NULL
some	NULL
of	NULL
our	NULL
donors	NULL
with	NULL
a	NULL
corresponding	NULL
set	NULL
of	NULL
overlapping	NULL
peptides	NULL
covering	NULL
the	NULL
complete	NULL
561-amino-acid	NULL
sequence	NULL
of	NULL
pp65	NULL
identified	NULL
several	NULL
individuals	NULL
who	NULL
,	NULL
despite	NULL
a	NULL
strong	NULL
response	NULL
to	NULL
one	NULL
or	NULL
several	NULL
IE-1-derived	NULL
peptides	NULL
,	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
any	NULL
of	NULL
the	NULL
pp6S5-derived	NULL
peptides	NULL
and	NULL
vice	NULL
versa	NULL
.	NULL

By	NULL
testing	NULL
the	NULL
pp65-derived	NULL
peptides	NULL
,	NULL
several	NULL
new	NULL
epitopes	NULL
were	NULL
identified	NULL
,	NULL
and	NULL
some	NULL
of	NULL
these	NULL
are	NULL
also	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
(	NULL
the	NULL
presenting	NULL
HLA	NULL
allomorphs	NULL
are	NULL
currently	NULL
being	NULL
determined	NULL
)	NULL
.	NULL

In	NULL
some	NULL
donors	NULL
,	NULL
the	NULL
responses	NULL
to	NULL
certain	NULL
peptides	NULL
were	NULL
clearly	NULL
positive	NULL
(	NULL
a	NULL
distinct	NULL
population	NULL
of	NULL
IFN-y-positive	NULL
events	NULL
not	NULL
observed	NULL
in	NULL
the	NULL
control	NULL
)	NULL
yet	NULL
extremely	NULL
small	NULL
.	NULL

For	NULL
example	NULL
,	NULL
in	NULL
D15	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
responsive	NULL
to	NULL
pp654ge_sq3	NULL
and	NULL
pp65493_sqp7	NULL
(	NULL
both	NULL
containing	NULL
the	NULL
known	NULL
epitope	NULL
sq3	NULL
)	NULL
was	NULL
only	NULL
0.02	NULL
%	NULL
,	NULL
while	NULL
0.78	NULL
%	NULL
responded	NULL
to	NULL
the	NULL
newly	NULL
identified	NULL
epitope	NULL
pPP65zGs	NULL
210	NULL
This	NULL
probably	NULL
illustrates	NULL
that	NULL
when	NULL
several	NULL
different	NULL
epitopes	NULL
can	NULL
be	NULL
presented	NULL
,	NULL
individual	NULL
peptides	NULL
may	NULL
become	NULL
dominant	NULL
epitopes	NULL
.	NULL

The	NULL
same	NULL
phenomenon	NULL
may	NULL
also	NULL
be	NULL
observed	NULL
in	NULL
8182	NULL
KERN	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

TABLE	NULL
1	NULL
.	NULL

Listing	NULL
of	NULL
identified	NULL
CD8*	NULL
T	NULL
cell	NULL
epitopes	NULL
in	NULL
IE-1	NULL
and	NULL
pp65*	NULL
IE-1	NULL
pp65	NULL
Donor	NULL
HLA	NULL
type	NULL
Peptide	NULL
z	NULL
``	NULL
Peptide	NULL
%	NULL
D1	NULL
AZ	NULL
,	NULL
A66	NULL
,	NULL
Bw6	NULL
,	NULL
B7	NULL
,	NULL
Cw7	NULL
,	NULL
B41	NULL
IF-1307	NULL
321	NULL
0.67	NULL
Not	NULL
tested	NULL
~173	NULL
87	NULL
0.50	NULL
D2	NULL
AZ	NULL
,	NULL
A3	NULL
,	NULL
Bw6	NULL
,	NULL
B7	NULL
,	NULL
Cw7	NULL
IFE-1307	NULL
321	NULL
0.47	NULL
PPSa13-4a27	NULL
``	NULL
0.20	NULL
~lisi-195	NULL
0.15	NULL
PPSairazi	NULL
'	NULL
0.33	NULL
D3	NULL
A3	NULL
,	NULL
Bw4	NULL
,	NULL
Bw6	NULL
,	NULL
B7	NULL
,	NULL
B51	NULL
,	NULL
Cw7	NULL
IF-1307	NULL
321	NULL
0.78	NULL
Not	NULL
tested	NULL
D4	NULL
Al	NULL
,	NULL
A3	NULL
,	NULL
Bw6	NULL
,	NULL
B7	NULL
,	NULL
B8	NULL
,	NULL
Cw7	NULL
IF-1307	NULL
321	NULL
5.46	NULL
Not	NULL
tested	NULL
IE-1	NULL
199-213	NULL
1.36	NULL
D5	NULL
Al	NULL
,	NULL
A2	NULL
,	NULL
Bw6	NULL
,	NULL
B8	NULL
,	NULL
B60	NULL
,	NULL
Cw3	NULL
,	NULL
Cw	NULL
?	NULL

7	NULL
2.72	NULL
PPS	NULL
3aso_s0s	NULL
``	NULL
0.13	NULL
``	NULL
1193-207	NULL
0.18	NULL
PPS	NULL
5ass-so7	NULL
``	NULL
0.10	NULL
IE-1199-213	NULL
0.17	NULL
D6	NULL
Al	NULL
,	NULL
A29	NULL
,	NULL
Bw4	NULL
,	NULL
Bw6	NULL
,	NULL
B8	NULL
,	NULL
B57	NULL
,	NULL
Cw6	NULL
IE-1g5_99	NULL
1.59	NULL
None*	NULL
None	NULL
D7	NULL
AZ	NULL
,	NULL
B35	NULL
,	NULL
B37	NULL
,	NULL
Cw2	NULL
,	NULL
Cw9	NULL
IE-1a1	NULL
43s	NULL
0.13	NULL
PPS	NULL
aso-sos	NULL
0.19	NULL
PPS	NULL
0.55	NULL
D8	NULL
Al	NULL
,	NULL
A3	NULL
,	NULL
Bw4	NULL
,	NULL
B37	NULL
,	NULL
Cw6	NULL
IE-1	NULL
389	NULL
303	NULL
1.44	NULL
None	NULL
None	NULL
D9	NULL
A3	NULL
,	NULL
A23	NULL
,	NULL
Bw4	NULL
,	NULL
Bw6	NULL
,	NULL
B37	NULL
,	NULL
B62	NULL
,	NULL
Cw3	NULL
,	NULL
Cw6	NULL
IE-1	NULL
isi_195	NULL
0.56	NULL
Not	NULL
tested	NULL
D10	NULL
Al	NULL
,	NULL
Bw6	NULL
,	NULL
B8	NULL
,	NULL
Cw7	NULL
85	NULL
99	NULL
1.73	NULL
None	NULL
None	NULL
IE-1	NULL
193-207	NULL
0.22	NULL
Dil	NULL
Al	NULL
,	NULL
B8	NULL
,	NULL
B44	NULL
,	NULL
Cw4	NULL
,	NULL
Cw7	NULL
IE-1	NULL
193-207	NULL
2.17	NULL
Not	NULL
tested	NULL
-1199—213	NULL
146	NULL
D12	NULL
Al	NULL
,	NULL
AZ	NULL
,	NULL
Bw4	NULL
,	NULL
Bw6	NULL
,	NULL
B52	NULL
,	NULL
B61	NULL
,	NULL
Cw3	NULL
IE-1379_393	NULL
0.46	NULL
PPS	NULL
280303	NULL
1.03	NULL
PPS3203-307	NULL
0.90	NULL
PPS	NULL
aso-5os	NULL
ND	NULL
PPS	NULL
0.16	NULL
PPS	NULL
0.15	NULL
D13	NULL
A30	NULL
,	NULL
A32	NULL
,	NULL
Bw4	NULL
,	NULL
B49	NULL
,	NULL
B51	NULL
,	NULL
Cw7	NULL
None	NULL
None	NULL
PPS	NULL
100-123	NULL
0.16	NULL
D14	NULL
AZ	NULL
,	NULL
A28	NULL
,	NULL
Bw4	NULL
,	NULL
B27	NULL
,	NULL
B37	NULL
,	NULL
Cw3	NULL
,	NULL
Cw6	NULL
None	NULL
None	NULL
PPS	NULL
205-219	NULL
0.78	NULL
PPS	NULL
aso-sos	NULL
0.02	NULL
PPS	NULL
0.02	NULL
D15	NULL
A2	NULL
,	NULL
A30/31	NULL
,	NULL
Bw6	NULL
,	NULL
B8	NULL
,	NULL
B60	NULL
,	NULL
Cw3	NULL
,	NULL
Cw7	NULL
None	NULL
None	NULL
PPS	NULL
aso-sos	NULL
0.33	NULL
PPS3a93-so7	NULL
0.30	NULL
D16-D18	NULL
B7	NULL
...	NULL
IE-1307	NULL
321°	NULL
None	NULL
Not	NULL
tested	NULL
Not	NULL
tested	NULL
``	NULL
All	NULL
peptides	NULL
giving	NULL
positive	NULL
responses	NULL
are	NULL
listed	NULL
for	NULL
each	NULL
donor	NULL
.	NULL

The	NULL
complete	NULL
sets	NULL
of	NULL
overlapping	NULL
15-mer	NULL
peptides	NULL
covering	NULL
the	NULL
complete	NULL
sequences	NULL
of	NULL
IE-1	NULL
and	NULL
pp65	NULL
were	NULL
tested	NULL
.	NULL

®	NULL
Percentage	NULL
of	NULL
total	NULL
CD8*	NULL
T	NULL
cells	NULL
expressing	NULL
IFN-y	NULL
(	NULL
background	NULL
from	NULL
control	NULL
samples	NULL
subtracted	NULL
)	NULL
.	NULL

©	NULL
Contains	NULL
the	NULL
known	NULL
HLA-B7-presented	NULL
epitopes	NULL
pp65,17	NULL
495	NULL
4nd	NULL
PP6S41q	NULL
496	NULL
(	NULL
12	NULL
)	NULL
.	NULL

``	NULL
Contains	NULL
the	NULL
known	NULL
HLA-A2	NULL
presented	NULL
epitope	NULL
PP65495	NULL
503	NULL
(	NULL
12	NULL
)	NULL
.	NULL

®	NULL
Negative	NULL
responses	NULL
were	NULL
defined	NULL
as	NULL
absence	NULL
of	NULL
a	NULL
population	NULL
of	NULL
positive	NULL
events	NULL
(	NULL
not	NULL
found	NULL
in	NULL
control	NULL
samples	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
unstimulated	NULL
samples	NULL
or	NULL
samples	NULL
with	NULL
irrelevant	NULL
peptide	NULL
)	NULL
with	NULL
at	NULL
least	NULL
50,000	NULL
CD3*	NULL
events	NULL
gated	NULL
.	NULL

Positive	NULL
events	NULL
in	NULL
control	NULL
samples	NULL
(	NULL
'background	NULL
'	NULL
)	NULL
ranged	NULL
from	NULL
0.01	NULL
to	NULL
0.06	NULL
%	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
.	NULL

T	NULL
pp6549a_so3	NULL
was	NULL
not	NULL
tested	NULL
individually	NULL
in	NULL
this	NULL
donor	NULL
for	NULL
lack	NULL
of	NULL
material	NULL
;	NULL
however	NULL
,	NULL
a	NULL
response	NULL
would	NULL
be	NULL
expected	NULL
(	NULL
like	NULL
pp65453_sq7	NULL
.	NULL

it	NULL
contains	NULL
the	NULL
known	NULL
HLA-A2	NULL
presented	NULL
epitope	NULL
pP6S49s_so3	NULL
)	NULL
-	NULL
4	NULL
By	NULL
way	NULL
of	NULL
exclusion	NULL
,	NULL
this	NULL
peptide	NULL
was	NULL
found	NULL
to	NULL
be	NULL
HLA-B7	NULL
presented	NULL
(	NULL
see	NULL
HLA	NULL
types	NULL
in	NULL
bold	NULL
type	NULL
in	NULL
the	NULL
table	NULL
)	NULL
and	NULL
was	NULL
the	NULL
only	NULL
peptide	NULL
tested	NULL
in	NULL
these	NULL
HCMV	NULL
IgG-seronegative	NULL
,	NULL
HLA-B7-positive	NULL
controls	NULL
.	NULL

Responses	NULL
did	NULL
not	NULL
exceed	NULL
those	NULL
from	NULL
unstimulated	NULL
samples	NULL
(	NULL
0.01	NULL
to	NULL
0.06	NULL
%	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
)	NULL
.	NULL

other	NULL
donors	NULL
,	NULL
where	NULL
single	NULL
peptides	NULL
give	NULL
much	NULL
stronger	NULL
responses	NULL
than	NULL
others	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
donors	NULL
reactive	NULL
to	NULL
both	NULL
pp65	NULL
and	NULL
IE-1	NULL
,	NULL
the	NULL
frequencies	NULL
of	NULL
responsive	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
compared	NULL
;	NULL
however	NULL
,	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
responses	NULL
obtained	NULL
with	NULL
overlapping	NULL
peptides	NULL
can	NULL
not	NULL
simply	NULL
be	NULL
added	NULL
,	NULL
since	NULL
complete	NULL
or	NULL
partial	NULL
epitopes	NULL
may	NULL
be	NULL
contained	NULL
in	NULL
the	NULL
overlap	NULL
.	NULL

More	NULL
important	NULL
than	NULL
the	NULL
difference	NULL
in	NULL
the	NULL
frequencies	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
respond	NULL
ing	NULL
to	NULL
one	NULL
or	NULL
the	NULL
other	NULL
protein	NULL
in	NULL
donors	NULL
responsive	NULL
to	NULL
both	NULL
seems	NULL
to	NULL
be	NULL
the	NULL
fact	NULL
that	NULL
some	NULL
donors	NULL
responded	NULL
to	NULL
only	NULL
one	NULL
of	NULL
the	NULL
two	NULL
proteins	NULL
.	NULL

So	NULL
far	NULL
we	NULL
have	NULL
tested	NULL
12	NULL
donors	NULL
with	NULL
both	NULL
complete	NULL
sets	NULL
of	NULL
peptides	NULL
.	NULL

In	NULL
total	NULL
,	NULL
7	NULL
donors	NULL
(	NULL
58	NULL
%	NULL
)	NULL
had	NULL
IE-1-specific	NULL
CD8*	NULL
T	NULL
cells	NULL
,	NULL
9	NULL
donors	NULL
(	NULL
75	NULL
%	NULL
)	NULL
had	NULL
pp6S5-specific	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
4	NULL
donors	NULL
(	NULL
33	NULL
%	NULL
)	NULL
had	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
responsive	NULL
to	NULL
both	NULL
proteins	NULL
.	NULL

Three	NULL
donors	NULL
(	NULL
25	NULL
%	NULL
)	NULL
responded	NULL
only	NULL
to	NULL
IE-1	NULL
,	NULL
and	NULL
5	NULL
(	NULL
42	NULL
%	NULL
)	NULL
responded	NULL
only	NULL
to	NULL
pp65	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
IE-1-specific	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
CD8	NULL
*-T-CELL	NULL
RESPONSE	NULL
TO	NULL
THE	NULL
HCMV	NULL
IE-1	NULL
PROTEIN	NULL
-	NULL
8183	NULL
6	NULL
t	NULL
6	NULL
A	NULL
``	NULL
1IE-13s07321	NULL
|	NULL
[	NULL
{	NULL
IE-lsor321	NULL
|	NULL
|	NULL
.	NULL

{	NULL
m	NULL
%	NULL
'	NULL
£	NULL
_	NULL
;	NULL
~	NULL
%	NULL
x	NULL
iﬁelevant	NULL
a	NULL
0.67	NULL
%	NULL
|	NULL
~I	NULL
N	NULL
peptide	NULL
6	NULL
;	NULL
;	NULL
&	NULL
+	NULL
T	NULL
T	NULL
87	NULL
T	NULL
T	NULL
10	NULL
aot	NULL
a¢	NULL
é	NULL
ac	NULL
@	NULL
aot	NULL
iG	NULL
¢	NULL
ast	NULL
®	NULL
dot	NULL
ig	NULL
1G	NULL
10	NULL
IFEN-y~FITC	NULL
--	NULL
»	NULL
IFN-yFITC	NULL
-	NULL
#	NULL
»	NULL
%	NULL
~	NULL
{	NULL
IE-1	NULL
308-316	NULL
IE-1310-318	NULL
£	NULL
0.02	NULL
%	NULL
ib-	NULL
I	NULL
U	NULL
I	NULL
10	NULL
10	NULL
!	NULL

10	NULL
10	NULL
106	NULL
IFN-yFHITC	NULL
6	NULL
6	NULL
.	NULL

[	NULL
IE-1311319	NULL
|	NULL
,	NULL
,	NULL
{	NULL
IE-1312320	NULL
aik	NULL
;	NULL
~	NULL
°	NULL
-	NULL
``	NULL
3	NULL
°	NULL
0.17	NULL
%	NULL
|	NULL
©	NULL
0.07	NULL
%	NULL
)	NULL
©	NULL
0.02	NULL
%	NULL
O	NULL
t	NULL
T	NULL
T	NULL
&	NULL
I	NULL
)	NULL
?	NULL

T	NULL
T	NULL
T	NULL
t	NULL
CU	NULL
ts	NULL
CI	NULL
10	NULL
-	NULL
dot	NULL
1¢	NULL
-	NULL
1Gi10	NULL
10	NULL
aot	NULL
4G	NULL
de	NULL
ac	NULL
10	NULL
aot	NULL
¢	NULL
ao	NULL
dof	NULL
IFN-yFITC	NULL
gm	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Fine	NULL
mapping	NULL
of	NULL
a	NULL
15-amino-acid	NULL
peptide	NULL
.	NULL

According	NULL
to	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
HLA-B7-presented	NULL
peptide	NULL
3	NULL
;	NULL
,	NULL
(	NULL
EFCRVLCCYVLEETS	NULL
)	NULL
,	NULL
seven	NULL
additional	NULL
nonamer	NULL
peptides	NULL
were	NULL
synthesized	NULL
and	NULL
tested	NULL
on	NULL
PBMC	NULL
of	NULL
an	NULL
HLA-B7-positive	NULL
donor	NULL
whose	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
reactive	NULL
to	NULL
the	NULL
original	NULL
peptide	NULL
(	NULL
top	NULL
)	NULL
.	NULL

Several	NULL
of	NULL
these	NULL
nonamer	NULL
peptides	NULL
led	NULL
to	NULL
IFN-y	NULL
induction	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
with	NULL
IE-1sp	NULL
,	NULL
317	NULL
giving	NULL
the	NULL
strongest	NULL
response	NULL
(	NULL
middle	NULL
and	NULL
bottom	NULL
)	NULL
.	NULL

IFN-y-positive	NULL
events	NULL
are	NULL
highlighted	NULL
.	NULL

The	NULL
activation	NULL
marker	NULL
CD69	NULL
is	NULL
used	NULL
to	NULL
increase	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
analysis	NULL
.	NULL

Results	NULL
for	NULL
50,000	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
displayed	NULL
.	NULL

PBMC	NULL
were	NULL
stained	NULL
with	NULL
anti-IFN-y-FITC	NULL
,	NULL
anti-CD69-PE	NULL
,	NULL
anti-CD8-PerCP	NULL
,	NULL
and	NULL
anti-CD3-APC	NULL
.	NULL

Axes	NULL
show	NULL
log	NULL
fluorescence	NULL
intensity	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
cells	NULL
exist	NULL
in	NULL
some	NULL
but	NULL
not	NULL
all	NULL
individuals	NULL
may	NULL
be	NULL
very	NULL
important	NULL
with	NULL
regard	NULL
to	NULL
IE-l-associated	NULL
immune	NULL
system	NULL
pathology	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

IE-1	NULL
is	NULL
known	NULL
to	NULL
induce	NULL
adhesion	NULL
molecule	NULL
upregulation	NULL
in	NULL
infected	NULL
cells	NULL
,	NULL
which	NULL
may	NULL
lead	NULL
to	NULL
nonspecific	NULL
activation	NULL
of	NULL
other	NULL
cells	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

This	NULL
process	NULL
is	NULL
not	NULL
disrupted	NULL
by	NULL
therapy	NULL
with	NULL
ganciclovir	NULL
or	NULL
foscarnet	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
IE-1-recognizing	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
such	NULL
a	NULL
situation	NULL
will	NULL
be	NULL
an	NULL
interesting	NULL
subject	NULL
to	NULL
study	NULL
.	NULL

Notably	NULL
,	NULL
all	NULL
donors	NULL
nonresponsive	NULL
to	NULL
the	NULL
pp65	NULL
peptides	NULL
were	NULL
HLA-A2	NULL
or	NULL
HLA-B7	NULL
negative	NULL
.	NULL

Conversely	NULL
,	NULL
most	NULL
individuals	NULL
not	NULL
responding	NULL
to	NULL
IE-1	NULL
were	NULL
HLA-A2	NULL
positive	NULL
and	NULL
HLA-B7	NULL
negative	NULL
.	NULL

The	NULL
data	NULL
,	NULL
though	NULL
preliminary	NULL
,	NULL
suggests	NULL
that	NULL
preferences	NULL
for	NULL
IE-1	NULL
over	NULL
pp65	NULL
and	NULL
vice	NULL
versa	NULL
are	NULL
directly	NULL
related	NULL
to	NULL
the	NULL
HLA	NULL
type	NULL
,	NULL
and	NULL
additional	NULL
studies	NULL
are	NULL
in	NULL
progress	NULL
to	NULL
corroborate	NULL
these	NULL
results	NULL
.	NULL

Dominant	NULL
peptides	NULL
may	NULL
be	NULL
derived	NULL
from	NULL
pp65	NULL
or	NULL
IE-1	NULL
,	NULL
and	NULL
clearly	NULL
there	NULL
is	NULL
no	NULL
obvious	NULL
hierarchy	NULL
of	NULL
presenting	NULL
allomorphs	NULL
at	NULL
this	NULL
stage	NULL
.	NULL

Interestingly	NULL
,	NULL
Gilbert	NULL
et	NULL
al	NULL
.	NULL

reported	NULL
in	NULL
1996	NULL
that	NULL
IE-1-specific	NULL
CTL	NULL
were	NULL
able	NULL
to	NULL
lyse	NULL
IE-1-transfected	NULL
but	NULL
not	NULL
HCMV-infected	NULL
autologous	NULL
fibroblasts	NULL
(	NULL
10	NULL
)	NULL
,	NULL
and	NULL
they	NULL
found	NULL
that	NULL
pp65	NULL
apparently	NULL
abrogated	NULL
IE-1	NULL
peptide	NULL
presentation	NULL
by	NULL
restricting	NULL
its	NULL
access	NULL
to	NULL
the	NULL
antigen-processing	NULL
machinery	NULL
or	NULL
diverting	NULL
it	NULL
to	NULL
a	NULL
different	NULL
degradation	NULL
pathway	NULL
.	NULL

This	NULL
in	NULL
contrast	NULL
to	NULL
earlier	NULL
data	NULL
obtained	NULL
by	NULL
Borysiewicz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
who	NULL
found	NULL
that	NULL
in	NULL
two	NULL
subjects	NULL
,	NULL
18	NULL
to	NULL
58	NULL
%	NULL
of	NULL
the	NULL
CTL	NULL
clones	NULL
able	NULL
to	NULL
lyse	NULL
HCMV	NULL
-infected	NULL
autologous	NULL
fibroblasts	NULL
were	NULL
IE-1	NULL
specific	NULL
(	NULL
2	NULL
)	NULL
.	NULL

In	NULL
their	NULL
study	NULL
,	NULL
only	NULL
a	NULL
small	NULL
number	NULL
of	NULL
IE-1-specific	NULL
CTL	NULL
clones	NULL
were	NULL
unable	NULL
to	NULL
lyse	NULL
HCMV	NULL
-infected	NULL
targets	NULL
.	NULL

The	NULL
phenomenon	NULL
described	NULL
by	NULL
Gilbert	NULL
et	NULL
al	NULL
.	NULL

may	NULL
thus	NULL
apply	NULL
to	NULL
only	NULL
some	NULL
IE-1-specific	NULL
clones	NULL
.	NULL

This	NULL
could	NULL
be	NULL
explained	NULL
if	NULL
some	NULL
but	NULL
not	NULL
all	NULL
IE-1	NULL
epitopes	NULL
escaped	NULL
presentation	NULL
under	NULL
the	NULL
influence	NULL
of	NULL
pp65	NULL
.	NULL

Neverthe-less	NULL
,	NULL
the	NULL
high	NULL
frequencies	NULL
of	NULL
IE-1-specific	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
our	NULL
donors	NULL
clearly	NULL
argue	NULL
that	NULL
sufficient	NULL
presentation	NULL
of	NULL
IE-1-derived	NULL
peptides	NULL
takes	NULL
place	NULL
for	NULL
these	NULL
cells	NULL
to	NULL
be	NULL
generated	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
in	NULL
this	NULL
regard	NULL
that	NULL
in	NULL
HCMV	NULL
reactivation	NULL
,	NULL
IE	NULL
proteins	NULL
are	NULL
expressed	NULL
prior	NULL
to	NULL
the	NULL
early	NULL
protein	NULL
pp65	NULL
(	NULL
whose	NULL
expression	NULL
is	NULL
regulated	NULL
by	NULL
IE-1-	NULL
and	NULL
IE-2-dependent	NULL
promot-ers	NULL
)	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
indicate	NULL
that	NULL
HCMV	NULL
reactivation	NULL
is	NULL
a	NULL
frequent	NULL
event	NULL
even	NULL
in	NULL
healthy	NULL
donors	NULL
(	NULL
23	NULL
)	NULL
,	NULL
seems	NULL
to	NULL
be	NULL
stress	NULL
related	NULL
,	NULL
and	NULL
is	NULL
probably	NULL
mediated	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
TNF-a	NULL
)	NULL
(	NULL
6	NULL
,	NULL
23	NULL
)	NULL
.	NULL

To	NULL
compile	NULL
a	NULL
selection	NULL
of	NULL
epitopes	NULL
which	NULL
may	NULL
be	NULL
useful	NULL
for	NULL
immunotherapy	NULL
in	NULL
a	NULL
majority	NULL
of	NULL
the	NULL
population	NULL
,	NULL
additional	NULL
work	NULL
must	NULL
be	NULL
done	NULL
.	NULL

Since	NULL
the	NULL
protein-coding	NULL
content	NULL
of	NULL
HCMV	NULL
is	NULL
enormous	NULL
,	NULL
it	NULL
will	NULL
hardly	NULL
be	NULL
possible	NULL
to	NULL
scan	NULL
all	NULL
proteins	NULL
for	NULL
epitopes	NULL
.	NULL

However	NULL
,	NULL
the	NULL
need	NULL
to	NULL
identify	NULL
T-cell	NULL
targets	NULL
in	NULL
HCMV	NULL
proteins	NULL
will	NULL
increase	NULL
if	NULL
vaccination	NULL
trials	NULL
using	NULL
,	NULL
for	NULL
example	NULL
,	NULL
the	NULL
AZ-presented	NULL
are	NULL
Success	NULL
8184	NULL
KERN	NULL
ET	NULL
AL	NULL
.	NULL

ful	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
should	NULL
encourage	NULL
the	NULL
search	NULL
for	NULL
T-cell	NULL
epitopes	NULL
in	NULL
other	NULL
nonstructural	NULL
HCMV	NULL
proteins	NULL
to	NULL
complete	NULL
the	NULL
repertoire	NULL
of	NULL
peptides	NULL
which	NULL
may	NULL
be	NULL
potential	NULL
candidates	NULL
for	NULL
vaccine	NULL
development	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

REFERENCES	NULL
.	NULL

Alp	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
T.	NULL
D.	NULL
Allport	NULL
,	NULL
J	NULL
.	NULL

Van	NULL
Zanten	NULL
,	NULL
B.	NULL
Rodgers	NULL
,	NULL
J.	NULL
G.	NULL
Sissons	NULL
,	NULL
and	NULL
L.	NULL
K.	NULL
Borysiewiez	NULL
.	NULL

1991	NULL
.	NULL

Fine	NULL
specificity	NULL
of	NULL
cellular	NULL
immune	NULL
responses	NULL
in	NULL
humans	NULL
to	NULL
human	NULL
cytomegalovirus	NULL
immediate-early	NULL
1	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4812-4820.	NULL
.	NULL

Borysiewicz	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
J.	NULL
K.	NULL
Hickling	NULL
,	NULL
S.	NULL
Graham	NULL
,	NULL
J.	NULL
Sinclair	NULL
,	NULL
M.	NULL
P.	NULL
Cranage	NULL
,	NULL
G.	NULL
L.	NULL
Smith	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Sissons	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
cytomegalovirus-specific	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

Relative	NULL
frequency	NULL
of	NULL
stage-specific	NULL
CTL	NULL
recognizing	NULL
the	NULL
72-kD	NULL
immediate	NULL
carly	NULL
protein	NULL
and	NULL
glycoprotein	NULL
B	NULL
expressed	NULL
by	NULL
recombinant	NULL
vac-cinia	NULL
viruses	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

168:919-931.	NULL
.	NULL

Burns	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
J.	NULL
C.	NULL
Pooley	NULL
,	NULL
D.	NULL
J.	NULL
Walsh	NULL
,	NULL
G.	NULL
M.	NULL
Vercellotti	NULL
,	NULL
M.	NULL
L.	NULL
Weber	NULL
,	NULL
and	NULL
A.	NULL
Kovacs	NULL
.	NULL

1999	NULL
.	NULL

Intercellular	NULL
adhesion	NULL
molecule-1	NULL
expression	NULL
in	NULL
endothelial	NULL
cells	NULL
is	NULL
activated	NULL
by	NULL
cytomegalovirus	NULL
immediate	NULL
early	NULL
proteins	NULL
.	NULL

Transplantation	NULL
67:137-144.	NULL
.	NULL

Craigen	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Grundy	NULL
.	NULL

1996	NULL
.	NULL

Cytomegalovirus	NULL
induced	NULL
up-regu-	NULL
lation	NULL
of	NULL
LFA-3	NULL
(	NULL
CD58	NULL
)	NULL
and	NULL
ICAM-1	NULL
(	NULL
CD54	NULL
)	NULL
is	NULL
a	NULL
direct	NULL
viral	NULL
effect	NULL
that	NULL
is	NULL
not	NULL
prevented	NULL
by	NULL
ganciclovir	NULL
or	NULL
foscarnet	NULL
treatment	NULL
.	NULL

Transplantation	NULL
62	NULL
:	NULL
1102-1108.	NULL
.	NULL

Diamond	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
J.	NULL
York	NULL
,	NULL
J.	NULL
Y	NULL
.	NULL

Sun	NULL
,	NULL
C.	NULL
L.	NULL
Wright	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Forman	NULL
.	NULL

1997	NULL
.	NULL

Development	NULL
of	NULL
a	NULL
candidate	NULL
HLA	NULL
A*0201	NULL
restricted	NULL
peptide-based	NULL
vaccine	NULL
against	NULL
human	NULL
cytomegalovirus	NULL
infection	NULL
.	NULL

Blood	NULL
90:1751-1767.	NULL
.	NULL

Docke	NULL
,	NULL
W.	NULL
D.	NULL
,	NULL
S.	NULL
Prosch	NULL
,	NULL
E.	NULL
Fietze	NULL
,	NULL
V.	NULL
Kimel	NULL
,	NULL
H.	NULL
Zuckermann	NULL
,	NULL
C.	NULL
Klug	NULL
,	NULL
U.	NULL
Syrbe	NULL
,	NULL
H.	NULL
D.	NULL
Kruger	NULL
,	NULL
R.	NULL
yon	NULL
Baehr	NULL
,	NULL
and	NULL
H.	NULL
D.	NULL
Volk	NULL
.	NULL

1994	NULL
.	NULL

Cytomegalovirus	NULL
reactivation	NULL
and	NULL
tumour	NULL
necrosis	NULL
factor	NULL
.	NULL

Lancet	NULL
343:268-269.	NULL
.	NULL

Falk	NULL
,	NULL
K.	NULL
,	NULL
O.	NULL
Rotzschke	NULL
,	NULL
S.	NULL
Stevanovic	NULL
,	NULL
V.	NULL
Gnau	NULL
,	NULL
K.	NULL
Sparbier	NULL
,	NULL
G.	NULL
Jung	NULL
,	NULL
H.-G.	NULL
Rammensee	NULL
,	NULL
and	NULL
P.	NULL
Walden	NULL
.	NULL

1994	NULL
.	NULL

Analysis	NULL
of	NULL
a	NULL
naturally	NULL
occurring	NULL
HLA	NULL
class	NULL
T-restricted	NULL
viral	NULL
epitope	NULL
.	NULL

Immunology	NULL
82:337-342.	NULL
.	NULL

Falk	NULL
,	NULL
K.	NULL
,	NULL
O.	NULL
Rotzschke	NULL
,	NULL
S.	NULL
Stevanovic	NULL
,	NULL
G.	NULL
Jung	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Rammensee	NULL
.	NULL

1991	NULL
.	NULL

Allele-specific	NULL
motifs	NULL
revealed	NULL
by	NULL
sequencing	NULL
of	NULL
self-peptides	NULL
eluted	NULL
from	NULL
MHC	NULL
molecules	NULL
.	NULL

Nature	NULL
351:290-296.	NULL
.	NULL

Gavin	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
M.	NULL
J.	NULL
Gilbert	NULL
,	NULL
S.	NULL
R.	NULL
Riddell	NULL
,	NULL
P.	NULL
D.	NULL
Greenberg	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Bevan	NULL
.	NULL

1993	NULL
.	NULL

Alkali	NULL
hydrolysis	NULL
of	NULL
recombinant	NULL
proteins	NULL
allows	NULL
for	NULL
the	NULL
rapid	NULL
identification	NULL
of	NULL
class	NULL
I	NULL
MHC-restricted	NULL
CTL	NULL
epitopes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:3971-3980	NULL
.	NULL

Gilbert	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
R.	NULL
Riddell	NULL
,	NULL
B.	NULL
Plachter	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Greenberg	NULL
.	NULL

1996	NULL
.	NULL

Cytomegalovirus	NULL
selectively	NULL
blocks	NULL
antigen	NULL
processing	NULL
and	NULL
presentation	NULL
of	NULL
its	NULL
immediate-carly	NULL
gene	NULL
product	NULL
.	NULL

Nature	NULL
383:720-722	NULL
.	NULL

Greenberg	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
P.	NULL
Reusser	NULL
,	NULL
J.	NULL
M.	NULL
Goodrich	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Riddell	NULL
.	NULL

1991	NULL
.	NULL

Development	NULL
of	NULL
a	NULL
treatment	NULL
regimen	NULL
for	NULL
human	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
infection	NULL
in	NULL
bone	NULL
marrow	NULL
transplantation	NULL
recipients	NULL
by	NULL
adoptive	NULL
transfer	NULL
of	NULL
donor-derived	NULL
CMV-specific	NULL
T	NULL
cell	NULL
clones	NULL
expanded	NULL
in	NULL
vitro	NULL
.	NULL

Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

636:184-195	NULL
.	NULL

Kern	NULL
,	NULL
F.	NULL
,	NULL
I.	NULL
P.	NULL
Surel	NULL
,	NULL
C.	NULL
Brock	NULL
,	NULL
B.	NULL
Freistedt	NULL
,	NULL
H.	NULL
Radtke	NULL
,	NULL
A.	NULL
Scheffold	NULL
,	NULL
R.	NULL
Blasczyk	NULL
,	NULL
P.	NULL
Reinke	NULL
,	NULL
J.	NULL
Schneider-Mergener	NULL
,	NULL
A.	NULL
Radbruch	NULL
,	NULL
P.	NULL
Walden	NULL
,	NULL
and	NULL
H.	NULL
D.	NULL
Volk	NULL
.	NULL

1998	NULL
.	NULL

T-cell	NULL
epitope	NULL
mapping	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

4:975-978	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

McLaughlin-Taylor	NULL
,	NULL
E.	NULL
,	NULL
H.	NULL
Pande	NULL
,	NULL
S.	NULL
J.	NULL
Forman	NULL
,	NULL
B.	NULL
Tanamachi	NULL
,	NULL
C.	NULL
R.	NULL
Li	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Zaia	NULL
,	NULL
P.	NULL
D.	NULL
Greenberg	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Riddell	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
major	NULL
late	NULL
human	NULL
cytomegalovirus	NULL
matrix	NULL
protein	NULL
pp65	NULL
as	NULL
a	NULL
target	NULL
antigen	NULL
for	NULL
CD8*	NULL
virus-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Virol	NULL
.	NULL

43:103-110	NULL
.	NULL

Quinnan	NULL
,	NULL
G.	NULL
V.	NULL
,	NULL
Jr.	NULL
,	NULL
W.	NULL
H.	NULL
Burns	NULL
,	NULL
N.	NULL
Kirmani	NULL
,	NULL
A.	NULL
H.	NULL
Rook	NULL
,	NULL
J.	NULL
Manischewitz	NULL
,	NULL
L.	NULL
Jackson	NULL
,	NULL
G.	NULL
W.	NULL
Santos	NULL
,	NULL
and	NULL
R.	NULL
Saral	NULL
.	NULL

1984	NULL
.	NULL

HLA-restricted	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
are	NULL
an	NULL
early	NULL
immune	NULL
response	NULL
and	NULL
important	NULL
defense	NULL
mechanism	NULL
in	NULL
cytomegalovirus	NULL
infections	NULL
.	NULL

Rev	NULL
.	NULL

Infect	NULL
.	NULL

Dis	NULL
.	NULL

6:156-163	NULL
.	NULL

Quinnan	NULL
,	NULL
G.	NULL
V.	NULL
,	NULL
Jr.	NULL
,	NULL
N.	NULL
Kirmani	NULL
,	NULL
A.	NULL
H.	NULL
Rook	NULL
,	NULL
J.	NULL
F.	NULL
Manischewitz	NULL
,	NULL
L.	NULL
Jackson	NULL
,	NULL
G.	NULL
Moreschi	NULL
,	NULL
G.	NULL
W.	NULL
Santos	NULL
,	NULL
R.	NULL
Saral	NULL
,	NULL
and	NULL
W.	NULL
H.	NULL
Burns	NULL
.	NULL

1982	NULL
.	NULL

Cytotoxic	NULL
T	NULL
cells	NULL
in	NULL
cytomegalovirus	NULL
infection	NULL
:	NULL
HLA-restricted	NULL
T-lymphocyte	NULL
and	NULL
non-T-lymphocyte	NULL
cytotoxic	NULL
responses	NULL
correlate	NULL
with	NULL
recovery	NULL
from	NULL
cytomegalovirus	NULL
infection	NULL
in	NULL
bone-marrow-transplant	NULL
recipients	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

307:7-13	NULL
.	NULL

Rammensee	NULL
,	NULL
H.	NULL
G.	NULL
,	NULL
J.	NULL
Bachmann	NULL
,	NULL
N.	NULL
Emmerich	NULL
,	NULL
and	NULL
S.	NULL
Stevanovic	NULL
.	NULL

15	NULL
January	NULL
1999	NULL
,	NULL
posting	NULL
date	NULL
.	NULL

SYFPEITHI-an	NULL
Internet	NULL
database	NULL
for	NULL
MHC	NULL
ligands	NULL
and	NULL
peptide	NULL
motifs	NULL
.	NULL

[	NULL
Online	NULL
]	NULL
http	NULL
;	NULL
//134.2.96.221/scripts/hlaserver.dll	NULL
/home.htm	NULL
.	NULL

[	NULL
20	NULL
April	NULL
1999	NULL
,	NULL
last	NULL
date	NULL
accessed	NULL
.	NULL
]	NULL

Rammensee	NULL
,	NULL
H.	NULL
G.	NULL
,	NULL
J.	NULL
Bachmann	NULL
,	NULL
and	NULL
S.	NULL
Stevanovic	NULL
.	NULL

1997	NULL
.	NULL

MHC	NULL
ligands	NULL
and	NULL
peptide	NULL
motifs	NULL
.	NULL

Landes	NULL
Bioscience	NULL
,	NULL
Georgetown	NULL
,	NULL
Tex	NULL
.	NULL

Rammensee	NULL
,	NULL
H.	NULL
G.	NULL
,	NULL
T.	NULL
Friede	NULL
,	NULL
and	NULL
S.	NULL
Stevanovic	NULL
.	NULL

1995	NULL
.	NULL

MHC	NULL
ligands	NULL
and	NULL
peptide	NULL
motifs	NULL
:	NULL
first	NULL
listing	NULL
.	NULL

Immunogenetics	NULL
41:178-228	NULL
.	NULL

Reusser	NULL
,	NULL
P.	NULL
,	NULL
S.	NULL
R.	NULL
Riddell	NULL
,	NULL
J.	NULL
D.	NULL
Meyers	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Greenberg	NULL
.	NULL

1991	NULL
.	NULL

Cytotoxic	NULL
T-lymphocyte	NULL
response	NULL
to	NULL
cytomegalovirus	NULL
after	NULL
human	NULL
allogeneic	NULL
bone	NULL
marrow	NULL
transplantation	NULL
:	NULL
pattern	NULL
of	NULL
recovery	NULL
and	NULL
correlation	NULL
with	NULL
cytomegalovirus	NULL
infection	NULL
and	NULL
disease	NULL
.	NULL

Blood	NULL
78:1373-1380	NULL
.	NULL

Riddell	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
P.	NULL
Reusser	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Greenberg	NULL
.	NULL

1991	NULL
.	NULL

Cytotoxic	NULL
T	NULL
cells	NULL
specific	NULL
for	NULL
cytomegalovirus	NULL
:	NULL
a	NULL
potential	NULL
therapy	NULL
for	NULL
immunocompromised	NULL
patients	NULL
.	NULL

Rev	NULL
.	NULL

Infect	NULL
.	NULL

Dis	NULL
.	NULL

11:966-973	NULL
.	NULL

Riddell	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Walter	NULL
,	NULL
M.	NULL
J.	NULL
Gilbert	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Greenberg	NULL
.	NULL

1994	NULL
.	NULL

Selective	NULL
reconstitution	NULL
of	NULL
CD8	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
responses	NULL
in	NULL
im-munodeficient	NULL
bone	NULL
marrow	NULL
transplant	NULL
recipients	NULL
by	NULL
the	NULL
adoptive	NULL
transfer	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

Bone	NULL
Marrow	NULL
Transplant	NULL
.	NULL

4:78-84	NULL
.	NULL

Stenberg	NULL
,	NULL
R.	NULL
M.	NULL
1993	NULL
.	NULL

Immediate-carly	NULL
genes	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
:	NULL
organization	NULL
and	NULL
function	NULL
,	NULL
p.	NULL
330-359	NULL
.	NULL

In	NULL
Y.	NULL
Becker	NULL
,	NULL
G.	NULL
Darai	NULL
,	NULL
and	NULL
E.	NULL
S.	NULL
Huang	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Molecular	NULL
aspects	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
diseases	NULL
.	NULL

Spring-er-Verlag	NULL
KG	NULL
,	NULL
Berlin	NULL
,	NULL
Germany	NULL
.	NULL

Toro	NULL
,	NULL
A.	NULL
L	NULL
,	NULL
and	NULL
J.	NULL
Ossa	NULL
.	NULL

1996	NULL
.	NULL

PCR	NULL
activity	NULL
of	NULL
CMV	NULL
in	NULL
healthy	NULL
CMV-seropositive	NULL
individuals	NULL
:	NULL
does	NULL
latency	NULL
need	NULL
redefinition	NULL
?	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

147:233-238	NULL
.	NULL

Walter	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
P.	NULL
D.	NULL
Greenberg	NULL
,	NULL
M.	NULL
J.	NULL
Gilbert	NULL
,	NULL
R.	NULL
J.	NULL
Finch	NULL
,	NULL
K.	NULL
S.	NULL
Watanabe	NULL
,	NULL
E.	NULL
D.	NULL
Thomas	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Riddell	NULL
.	NULL

1995	NULL
.	NULL

Reconstitution	NULL
of	NULL
cellular	NULL
immunity	NULL
against	NULL
cytomegalovirus	NULL
in	NULL
recipients	NULL
of	NULL
allogeneic	NULL
bone	NULL
marrow	NULL
by	NULL
transfer	NULL
of	NULL
T-cell	NULL
clones	NULL
from	NULL
the	NULL
donor	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

333:1038-1044	NULL
.	NULL

Wills	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
A.	NULL
J.	NULL
Carmichael	NULL
,	NULL
K.	NULL
Mynard	NULL
,	NULL
X.	NULL
Jin	NULL
,	NULL
M.	NULL
P.	NULL
Weekes	NULL
,	NULL
B.	NULL
Plachter	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Sissons	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
human	NULL
cytotoxic	NULL
T-lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
response	NULL
to	NULL
cytomegalovirus	NULL
is	NULL
dominated	NULL
by	NULL
structural	NULL
protein	NULL
pp65	NULL
:	NULL
frequency	NULL
,	NULL
spec-ificity	NULL
,	NULL
and	NULL
T-cell	NULL
receptor	NULL
usage	NULL
of	NULL
ppéS-specific	NULL
CTL	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:7569-7579	NULL
.	NULL

